i2E, Inc., recently closed a $325,000 investment in Oklahoma City-based DermaMedics, LLC, a growing health care business. The i2E investment was part of a financing round with co-investors that totaled $1.5 million.

DermaMedics produces and markets topical anti-inflammatory products to prevent burns in cancer patients and in patients undergoing cosmetic procedures, as well as products to treat a variety of common skin diseases such as psoriasis, acne, eczema and rosacea, and skin aging. The company's unique products are based on technology developed at the University of Oklahoma Health Sciences Center by Bryan Fuller, Ph.D., a professor and skin biochemistry researcher who left the university in 2006 to establish a business to commercialize his discoveries.

The investment was made through the OKAngel Sidecar Fund, one of three investment vehicles created by i2E through Accelerate Oklahoma! partnership with the Oklahoma Department of Commerce and the U.S. Treasury State Small Business Credit Initiative.

The co-investment ratio with the federal funds upon closing is 2:1 and subsequent investments and traditional financing are expected to result in a greater leverage ratio within five years.

About DermaMedics, LLC

Bryan Fuller, Ph.D., CEO

Year started: 2010

Location: Oklahoma City

No. of current employees: 14

Future plans: DermaMedics has already launched the sales of its therapeutic products to professional accounts and will increase its sales nationwide by using a professional sales force. The sales professionals will call on four target markets: physician offices/clinics, medical spas, cancer centers performing radiation therapy and independent pharmacies.

About i2E, Inc.: With offices in Oklahoma City and Tulsa, OK, not-for-profit i2E provides an award-winning suite of venture advisory, access to capital and entrepreneurial development programs for Oklahoma's high growth businesses.